News
-
Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug… Read more . . .
-
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis… Read more . . .
-
Retrophin has announced that Stephen Aselage will take over as interim CEO immediately, replacing company founder and CEO Martin Shkreli. According to reports, Shkreli was fired for “stock trading irregularities” and other rules violations. Aselage… Read more . . .
-
Twenty-five years after its first meeting in a Glaxo Group Research lecture theater, the Aerosol Society’s annual Drug Delivery to the Lungs conference marks its silver anniversary with DDL 25, taking place December 10-12 at… Read more . . .
-
Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said,… Read more . . .
-
According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company’s naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for… Read more . . .
-
Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for… Read more . . .
-
Sunovion Pharmaceuticals has announced that it will sell “certain rights” to its Xopenex levalbuterol inhalation solution to Akorn for $45 million. Rights to the Xopenex HFA MDI are being retained by Sunovion. Akorn says that… Read more . . .
-
Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, “The… Read more . . .
-
Consort Medical, the parent company of device supplier Bespak, has announced that it will acquire CDMO Aesica Pharmaceuticals for £230 million, with the deal expected to be complete in November, 2014. Aesica offers development and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.